[Progress of studies on enhancing efficiency of gene transfection into hematopoietic cells with the adenoviral vector--review].
Recombinant adenoviral vectors have been widely applied for the basic research and clinical trials of gene therapy. However, the inability of adenovirus to infect hematopoietic cells which lack the specific adenovirus receptors-coxsackie virus and adenovirus receptor (CAR) represents an important limitation in therapeutic applications. This limitation may be overcome by several approaches including modification of adenovirus vector and improvement of the susceptibility of hematopoietic cells. The current progresses in this field were summarized.
Wang
Li-Sha
LS
Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China.
Duan
Hai-Feng
HF
Wang
Li-Sheng
LS
D000256:Adenoviridae / Q000235:genetics*; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D015316:Genetic Therapy; D006412:Hematopoietic Stem Cells / Q000378:metabolism*; D006801:Humans; D011991:Receptors, Virus / Q000235:genetics*; D014162:Transfection
C568771:CLMP protein, human; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D011991:Receptors, Virus